NRx Pharmaceuticals Inc. [NASDAQ: NRXP] stock went on a downward path that fall over -7.47% on Monday, amounting to a one-week price decrease of less than -6.95%. The company report on August 14, 2023 at 4:01 PM that NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update.
Two near-term data catalysts expected in 2023.
Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal bipolar depression; potential for up to $330 million in milestones and double-digit royalties.
Over the last 12 months, NRXP stock dropped by -59.89%. The one-year NRx Pharmaceuticals Inc. stock forecast points to a potential upside of 93.58. The average equity rating for NRXP stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $25.72 million, with 73.22 million shares outstanding and 52.89 million shares in the current float. Compared to the average trading volume of 906.81K shares, NRXP stock reached a trading volume of 4712224 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on NRx Pharmaceuticals Inc. [NRXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRXP shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRXP stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
NRXP Stock Performance Analysis:
NRx Pharmaceuticals Inc. [NRXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.95. With this latest performance, NRXP shares dropped by -16.83% in over the last four-week period, additionally sinking by -70.69% over the last 6 months – not to mention a drop of -59.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NRXP stock in for the last two-week period is set at 38.51, with the RSI for the last a single of trading hit 39.11, and the three-weeks RSI is set at 38.25 for NRx Pharmaceuticals Inc. [NRXP]. The present Moving Average for the last 50 days of trading for this stock 0.3962, while it was recorded at 0.3082 for the last single week of trading, and 0.7841 for the last 200 days.
Insight into NRx Pharmaceuticals Inc. Fundamentals:
Return on Total Capital for NRXP is now -225.97, given the latest momentum, and Return on Invested Capital for the company is -256.17. Return on Equity for this stock declined to -281.79, with Return on Assets sitting at -135.81. When it comes to the capital structure of this company, NRx Pharmaceuticals Inc. [NRXP] has a Total Debt to Total Equity ratio set at 142.06. Additionally, NRXP Total Debt to Total Capital is recorded at 58.69, with Total Debt to Total Assets ending up at 40.77. Long-Term Debt to Equity for the company is recorded at 38.09, with the Long-Term Debt to Total Capital now at 15.74.
NRx Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 0.90.
NRx Pharmaceuticals Inc. [NRXP] Institutonal Ownership Details
The top three institutional holders of NRXP stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in NRXP stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in NRXP stock with ownership which is approximately 5.7381%.